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Abstract: A long-acting form of the second-generation antipsychotic drug risperidone is now 
broadly available for the treatment of schizophrenia and closely related psychiatric conditions. 
It combines the advantage of previously available depot formulations for ﬁ  rst-generation drugs 
with the favorable characteristics of the modern “atypical” antipsychotics, namely higher efﬁ  cacy 
in the treatment of the negative symptoms of schizophrenia and reduced motor disturbances. 
Published clinical studies show an objective clinical efﬁ  cacy (as per psychiatric symptom scores 
and relapse data) that exceeds that of oral atypical antipsychotics when patients are switched 
to the long-acting injectable form, a low incidence of treatment-emergent extrapyramidal 
side effects, and very good acceptance by patients. Available data for maintenance treatment 
of bipolar disorder show equivalence with the oral form instead of superiority, but are still 
limited. As it seems likely that efﬁ  cacy beneﬁ  ts are mostly due to the fact that the injectable 
form reduces the demand for patient compliance to one physician visit every 2 weeks instead 
of self-administration on a daily or twice-daily basis, additional potential could exist in other 
psychiatric disorders where atypical antipsychotic drugs are of beneﬁ  t but where patient adher-
ence to treatment schedules is typically low.
Keywords: risperidone, schizophrenia, psychotic disorders, patient compliance; delayed-action 
preparations, injections, intramuscular
Depot antipsychotics: a necessity in a patient 
population inclined towards non-compliance
Premature discontinuation of antipsychotic drug therapy is a common phenomenon: 
in the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) study, 74% 
of patients discontinued their drug within 18 months due to either poor tolerability 
or lack of efﬁ  cacy (Lieberman et al 2005). Even among those who do not explicitly 
discontinue drug therapy, non-adherence to long-term oral medication regimes is one 
of the most signiﬁ  cant therapeutic issues in the therapy of schizophrenia and related 
disorders (Kane 2007; Byerly et al 2007). As a result, many of these patients do not 
experience the full beneﬁ  t of antipsychotic drug therapy, and suffer frequent relapses 
or exacerbations which require rehospitalization, often in the context of psychiatric 
emergency.
The consensus of many estimates in the literature places the fraction of outpatients 
who are at least to some signiﬁ  cant degree non-adherent to their antipsychotic therapy 
scheme at 40% or higher. Medication adherence during the early course of schizo-
phrenia is a strong predictor of long-term clinical outcome (Kane 2007; Bachmann 
et al 2008), but neither the individual patients themselves nor their psychiatrists seem 
able to reliably identify the degree of compliance with oral antipsychotic drug regimes 
(Velligan et al 2007). Failure to establish a therapeutic alliance with medical staff during 
acute hospitalization, lack of insight into the pathological nature of the symptoms of 
schizophrenia, concomitant substance abuse, and absence of family support are the most Neuropsychiatric Disease and Treatment 2008:4(5) 920
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signiﬁ  cant predictors of outpatient non-compliance (Olfson 
et al 2000). In a retrospective survey (Knapp et al 2004), 
those patients who self-reported non-adherence (likely only a 
fraction of those who deny non-adherence or are unaware of 
it) were much more likely to report use of inpatient services, 
and their external service cost is several times higher than for 
patients who state that they are compliant with antipsychotic 
medication regimes. Correlation analyses of pharmacy reﬁ  ll 
records and hospitalization statistics conﬁ  rm this (Gilmer 
et al 2004).
A steadily growing body of literature addresses this 
complex behavioral problem, in which factors related to 
the underlying psychiatric condition and adverse drug side 
effects are but two elements, with personal beliefs and atti-
tudes, psychosocial environment factors, and availability 
of healthcare resources also making decisive contributions. 
A recently published review (Weiden 2007) has stated very 
succinctly that if an easy answer to the problem of medica-
tion non-adherence in schizophrenia existed, it would have 
already been found.
Even during the early times of antipsychotic drug therapy, 
developers realized that depot formulations of antipsychotic 
drugs which can provide therapeutic plasma levels for sev-
eral weeks after a single intramascular injection could offer 
a way to partially circumvent the problem of noncompli-
ance in the therapy of schizophrenia. Such formulations of 
ﬁ  rst-generation antipsychotics which employ long-chain 
alkanoic acid (decanoate and/or enanthate) salts of haloperi-
dol, ﬂ  uphenazine, perphenazine, ﬂ  upenthixol, clopenthixol, 
and zuclopenthixol in plant oils became available from the 
1960s onward. The slow-release pharmacokinetics of these 
long-acting injectable (LAI) drugs (Jann et al 1985) made it 
possible to discharge stabilized but potentially non-compliant 
patients who would then have to return only once per month 
to receive their next depot injection (McEvoy 2006).
Use of classical depot antipsychotics declined in the 
1990s, a development that has been partially attributed to 
the introduction of the second-generation (“atypical”) anti-
psychotic drugs which exhibit higher efﬁ  cacy with respect 
to the treatment of negative symptoms of schizophrenia and 
reduced liability for motor side effects. However, these newer 
drugs were initially available as oral formulations only. By 
the ﬁ  rst years of the new millennium, psychiatrists were 
aware that, although patients treated with second-generation 
antipsychotics showed moderately better therapy adherence 
than those treated with older drugs, additional measures were 
required for those newer drugs as well (Dolder et al 2002), 
with long-acting formulations being the natural choice.
Formulation and pharmacological 
characteristics of risperidone 
long-acting injection
The LAI formulation of the well-established oral atypical 
antipsychotic risperidone became available in Europe from 
August 2002 onward, and was launched in the US in Decem-
ber 2003. It had been developed by the Janssen Research 
Foundation (Beerse, Belgium; a member of the Johnson 
and Johnson group of companies) using the Medisorb™ 
formulation technology provided by drug delivery specialist 
Alkermes, Inc. (Cambridge, Mass., USA). Risperidone LAI 
uses micrometer-sized biodegradable poly(d,l-lactide-co-
glycolide) microspheres which are loaded with risperidone 
and suspended in sterile saline. There is no signiﬁ  cant drug 
release immediately after injection; substantial release of 
risperidone into plasma begins only at 2 to 3 weeks post injec-
tion, increases during weeks 3 and 4, is maintained during 
weeks 4 through 6, and declines between weeks 6 and 7. With 
repeated injections every 2 weeks, steady-state levels are 
usually reached by weeks 6 to 8 (Knox and Stimmel 2004). 
Details on the plasma pharmacokinetic proﬁ  le ( Eerdekens 
et al 2004; Mannaert et al 2005) and on brain dopamine D2 
receptor occupancy (Gefvert et al 2005; Remington et al 
2006) have been published, showing bioequivalence between 
the oral and LAI versions but with reduced peak-trough 
ﬂ  uctuations in plasma levels of risperidone and its active 
metabolite, 9-hydroxyrisperidone (Nesvag et al 2006) which 
has been developed into a follow-on drug for risperidone (see 
separate section). Although similar experimental drug deliv-
ery systems have been reported for chlorpromazine (Suzuki 
and Price 1985) and haloperidol (Cheng et al 1998), no such 
formulation of any classical neuroleptic has ever reached the 
pharmacy shelves and Risperdal Consta was the ﬁ  rst atypical 
antipsychotic to become available as a LAI version.
Efﬁ  cacy and safety data
The ﬁ  rst data on clinical efﬁ  cacy and safety were initially 
presented in May 2001, and full results were subsequently 
published. In a 4-arm, 3-month, randomized, double-blind, 
placebo-controlled study conducted at 41 medical centers in 
the United States (Kane et al 2003), all 4 × 100 patients with 
schizophrenia were ﬁ  rst started on oral risperidone (maxi-
mum daily dose, 4 mg) and continued to receive oral risperi-
done for a total of 4 weeks. Patients in 3 study arms received 
1 of 3 doses of risperidone LAI (25 mg, 50 mg, or 75 mg) 
every 2 weeks, while the fourth was injected with placebo. 
Treatment with other antipsychotics was not permitted. Neuropsychiatric Disease and Treatment 2008:4(5) 921
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Patients who showed signs of relapse were removed from 
the study. All risperidone LAI treatment groups experienced 
signiﬁ  cantly greater improvements in their total Positive and 
Negative Symptom Scale (PANSS; the primary efﬁ  cacy out-
come measure) scores than those who received placebo (mean 
changes, −6.2, −8.5, and −7.4 for the three doses; p = 0.002 
for all doses). There were also more positive responses for 
risperidone LAI versus placebo for all of the secondary mea-
sures used in the study, including the PANSS subscales for 
positive and negative symptoms, the percentage of patients 
who experienced symptom improvement of at least 20%, and 
time to dropout due to lack of efﬁ  cacy. Thirty percent more 
patients on placebo, as opposed to 22%, 16%, and 12% for 
25 mg, 50 mg, and 75 mg, withdrew from the study due to 
insufﬁ  cient treatment response.
All doses were generally well tolerated. The percentage 
of patients who dropped out of the study due to side effects 
after receiving risperidone LAI in addition to the oral drug 
was 11% for 25 mg of risperidone LAI, 12% for 50 mg and 
14% for 75 mg, comparable to the discontinuation rate for 
additional placebo (12%). At the highest dose of risperidone 
LAI (without oral supplementation), the most common side 
effects that were reported with signiﬁ  cantly higher freqency 
by patients on risperidone LAI were headache (18% for ris-
peridone patients vs 13% for those receiving placebo), sleepi-
ness (11% vs 2%), and anxiety (11% vs 7%). Remarkably 
with respect to cardiac safety, there were fewer cases of QTc 
prolongation among patients taking all doses of risperidone 
LAI than among those taking placebo.
A subanalysis of 214 patients who were inpatients at 
study initiation (Lauriello et al 2005) showed risperidone 
LAI to be associated with a signiﬁ  cant reduction in total 
PANSS score (mean change ± standard error at endpoint: 
risperidone LAI, −9.27 ± 1.44, n = 133; placebo, 0.72 ± 2.59, 
n = 41; p  0.001), and a signiﬁ  cantly higher rate of treat-
ment response, deﬁ  ned as 20% reduction in total PANSS 
score (50% vs 27%, p  0.05).
Results from a larger (116 centers in 16 countries) study 
of much longer treatment duration (50 weeks), which, 
however, used an open label design, were ﬁ  rst reported in 
December 2001, and were later published in a long series of 
peer-reviewed papers (Fleischhacker et al 2003, 2005; Lasser 
et al 2004a, b, 2005; Leal et al 2004; Gharabawi et al 2005). 
The study was conducted from March 1999 to July 2000, and 
apart from not being blinded its design was similar to the 
study described previously. During a 2-week run-in period, 
patients were withdrawn from their prescribed antipsychotic 
(if different from risperidone) and received oral risperidone 
at 1–6 mg/day. Patients continued to take oral risperidone 
for another 2–4 weeks after injections of risperidone 
LAI (25, 50, or 75 mg every 2 weeks) began to assure that 
therapeutic blood levels of the drug were achieved prior to 
the halt in oral treatment. A total of 725 symptomatically 
stable patients with schizophrenia (n = 615) or schizoaffec-
tive disorder (n = 110) received at least 1 injection. Sixty-ﬁ  ve 
percent (n = 474) completed the study, receiving injections 
for a full 50 weeks. The primary measure of efﬁ  cacy was the 
PANSS. Global illness severity and patient-rated health status 
were measured using the Clinical Global Impressions (CGI) 
scale and the 36-Item Short-form (SF-36) Health Survey, 
respectively. Dyskinesia and other movement disorders, as 
rated by the Extrapyramidal Symptom Rating Scale (ESRS), 
were minimal: Five of 530 subjects without dyskinesia at 
baseline (0.94%) met the predeﬁ  ned criteria for emergent 
persistent tardive dyskinesia during therapy. Based on either 
exposure to study medication or Kaplan-Meier analysis, the 
1-year rate was 1.19%. Among the 132 subjects with dyski-
nesia at baseline, the mean score on the ESRS physician’s 
exam for dyskinesia improved signiﬁ  cantly at endpoint 
(−2.77; p  0.0001), regardless of anticholinergic drug use 
(Gharabawi et al 2005).
Remission (as deﬁ  ned by mild or better multiple core-
symptom ratings for at least 6 months) was achieved in 20.8% 
of those patients who did not meet the symptom-severity 
component of remission criteria at baseline, with signiﬁ  cant 
decreases in mean PANSS total and cluster scores. In these 
patients, endpoint changes from baseline were −4.8 ± 0.6 
for positive symptoms; −5.9 ± 0.5 for negative symptoms; 
−3.7 ± 0.4 for disorganized thoughts; −2.5 ± 0.4 for anxiety 
and depression, and −1.4 ± 0.3 for excitement and hostility 
(mean ± standard error; p  0.0001 for all scores). Patient-
rated health status was also signiﬁ  cantly improved. Percent-
ages rated as not ill, very mildly, or mildly symptomatic 
increased from 39% to 88%. Among 31.8% (184/578) of 
patients meeting the symptom-severity component of remis-
sion criteria at baseline, 84.8% (156) maintained these criteria 
at endpoint (Lasser et al 2005).
Only 5% of patients with schizophrenia dropped out of 
the study due to side effects, and although extrapyramidal 
symptoms were reported by 25% of the patients spontane-
ously reported tardive dyskinesia occurred in fewer than 1% 
of patients overall, and severity scores decreased in each 
of the groups during the 12 months of treatment. The other 
most common adverse events were anxiety in 24%, insom-
nia in 21%, psychosis in 17%, and depression in 14% of the 
patients. No medically relevant cases of QTc prolongation Neuropsychiatric Disease and Treatment 2008:4(5) 922
Rainer
were observed. Injection site pain (a typical complaint 
with the oil-based depot formulations of ﬁ  rst-generation 
antipsychotics) was reported by just two percent of patients 
who received risperidone LAI, consistent with the 12-week 
study. There was a modest increase of body weight (aver-
age for all doses of risperidone LAI, 2.5 kg) at the end of 
the treatment year. Healthcare resource utilization declined 
signiﬁ  cantly during this study. The number of patients needing 
any type of hospitalization decreased exponentially from 38% 
during the 12 weeks before study entry to 12% during the last 
12 weeks. Outpatient consultations also decreased signiﬁ  -
cantly from 70% of patients to 30% in the ﬁ  rst 12 weeks of 
treatment and remained stable thereafter (Leal et al 2004).
Data were collected for a prospective, double-blind, 
randomized 1-year study (Simpson et al 2006) using the 
two approved doses of risperidone LAI from December 
2002 to September 2004. Time to relapse, deﬁ  ned as either 
re-hospitalization or other exacerbation criteria, was the 
primary outcome. Other assessments included the PANSS, 
CGI-Severity of Illness scale, and functional and quality-of-life 
measures. Safety was assessed via treatment-emergent adverse 
events, laboratory tests, and movement disorder rating scales. 
A total of 324 patients were randomized to 25 mg (N = 163) or 
50 mg (N = 161) of long-acting risperidone. Time to relapse 
was comparable (p = 0.131) for both groups. Projected median 
time to relapse was 161.8 weeks (95% CI = 103.0–254.2) with 
25 mg and 259.0 weeks (95% CI = 153.6–436.8) with 50 mg. 
One-year incidences of relapse were 21.6% (N = 35) and 
14.9% (N = 24), respectively (p = 0.059). Psychiatric hospi-
talization was the reason for relapse for 16 (10%) in the 25-mg 
group and 10 (6%) in the 50-mg group. Patients experienced 
statistically signiﬁ  cant but modest improvements at endpoint 
in most measures (ie, psychotic symptoms, functioning, move-
ment disorder severity) with both doses, with no signiﬁ  cant 
between-group differences.
Direct transition from oral 
antipsychotics to risperidone 
LAI: the StoRMi trial
An important issue for the acceptance of a new therapeutic 
option in clinical practice is how smoothly the transition 
from existing medications to the new one can be performed, 
and whether there are efﬁ  cacy or safety problems to be 
expected during the switching process or during the subse-
quent maintenance treatment. Initial promising information 
on this potential issue with risperidone LAI had already 
been provided by a 12-week multicentric open-label study 
(Lindenmayer et al 2004). Full-scale evaluation was the 
objective of the open-label, single-arm Switch To Risperi-
done Microspheres (StoRMi) trial which was performed at 
324 centers in 22 European countries between December 
2001 and March 2004 (Moller et al 2005). Patients with 
schizophrenia or other psychotic disorders received gluteal 
injections of risperidone LAI 25 mg every 2 weeks for 
6 months, without a run-in period with oral risperidone. Any 
stable oral antipsychotic therapy was allowed at enrollment; 
only patients who had been treated with clozapine during 
the previous 3 months, or who had known intolerance for 
risperidone, were excluded. After 24 weeks the dose could 
be increased to 37.5 mg or 50 mg in biweekly intervals. All 
patients continued on their previous antipsychotic regimen 
for the ﬁ  rst 3 weeks of risperidone LAI treatment. Of 1876 
patients enrolled, 74% completed the 6-month study and 22% 
received oral risperidone supplementation (mean modal dose, 
3.2 ± 2.4mg/day for a mean duration of 43.0 ± 42.0 days. 
There was a signiﬁ  cant reduction from baseline to endpoint 
in mean total PANSS score (from 73.4 ± 22.3 at baseline to 
63.1 ± 22.8 at endpont; p  0.001), with 38% of patients hav-
ing a 20% or higher improvement. The scores on all PANSS 
subscales and symptom factors also improved signiﬁ  cantly 
(p  0.001). These beneﬁ  ts were achieved regardless of 
symptom severity at baseline. The CGI severity score also 
improved signiﬁ  cantly (3.9 ± 1.1 vs 3.3 ± 1.3; p  0.001), 
as did the mean Global Assessment of Function score. It is 
important to note in this context that one third of all patients 
had been changed to risperidone LAI from their original oral 
treatment because of insufﬁ  cient efﬁ  cacy.
Transition to risperidone LAI and continued treatment 
was tolerated very well, both objectively and in the patient’s 
own impression. The proportion of patients who rated 
their satisfaction with treatment as “very good” increased 
from 6% to 31%. All factors on the SF-36 questionnaire 
improved; at endpoint, the scores at endpoint for Bodily 
Pain, Vitality, and the Physical Component Summary 
approached the normative values for the US population. 
Movement disorders were reported as treatment-emergent 
events by 12% of patients. However, the proportion of 
patients reporting onset of a movement disorder decreased 
from 4% during the ﬁ  rst month of treatment to 1% during 
months 4–6. ESRS scores showed continuous improvements 
throughout the study period, from 6.0 points at baseline to 
2.8 points at month 6. The Parkinsonism subscore of the 
ESRS paralleled this development. Of the 15 deaths that 
occurred during the study, 5 were attributable to cardiac 
arrest or other cardiovascular causes, which is consistent Neuropsychiatric Disease and Treatment 2008:4(5) 923
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with myocardial mortality rates typically observed in 
schizophrenia studies.
Apart from this comprehensive report by Moller et al 
(2005), various subgroup analyses have been published 
which grant valuable insights into the action spectrum of 
risperidone LAI.
The most signiﬁ  cant conclusion to be drawn from the 
synopsis of the results summarized in Table 1 is that objec-
tive treatment beneﬁ  t, safety, and patient satisfaction were 
very evenly distributed across the StoRMi population. The 
schizoaffective disorder subgroup reported by Mohl et al 
(2004) seems to be the only patient group showing less pro-
nounced response on the PANSS score. However, signiﬁ  cant 
improvements from baseline to endpoint were seen in the 
mood symptom domains of anxiety/depression (10.4 ± 4.1 
vs 8.7 ± 3.9) and uncontrolled hostility/excitement (7.6 ± 
3.6 vs 6.9 ± 3.8). The uncertainty concerning the diagnostic 
reliability for this heterogeneous clinical condition, which 
many pychiatrists see in a continuum with bipolar disorder, is 
a factor that must be considered in interpreting these results. 
Here, too, total ESRS movement disorder scores fell progres-
sively throughout the study, and the reduction was already 
statistically signiﬁ  cant (p  0.001) at 4 weeks.
Eighteen-month follow-up data on (initially) 529 par-
ticipants from the StoRMI trial have been published (Llorca 
et al 2008). The discontinuation rate (as per Kaplan-Meier 
statistics) was 55.7%, which was to a large part due to the fact 
that risperidone LAI had meanwhile become commercially 
available. (As per the study protocol, this terminated follow-
up.) Median time to discontinuation was 15.7 months (95% 
CI, 14.0–17.5). The treatment-emergent adverse event rate 
was 69% (comparable to what was seen in the formal part 
of StoRMI) and only 46 patients (8.7%) discontinued treat-
ment due to adverse events. Mean weight gain was minimal 
(1.0 kg), and not statistically signiﬁ  cant in patients who had a 
body mass index 25 kg/m2 at baseline. Of the patients who 
had achieved or maintained clinical remission during the ﬁ  rst 
6 months of risperidone LAI treatment during StoRMI, 94% 
Table 1 Major published subgroup analyses of the StoRMI trial
Subgroup Patient 
characteristics
PANSS score mean 
changes
SF-36 changes etc Treatment-emergent 
adverse events
Reference
Switch from 
ﬁ  rst-generation 
antipsychotic
100 patients 
switched from oral 
drug, 565 from 
depot medication
−15.3 ± 17.5 for switch 
from oral drug; –9.1 ± 
19.5 for switch from 
depot drug
CGI-S, GAF, SF-36 
improved on all meaures
58.0% for switch from 
oral drug; 60.4% for 
switch from depot drug
Marinis et al 
2007
Switch from 
monotherapy with 
Risperdal oral
568 patients (60% 
men, age 36–40 
yr); 429 (75%) 
completed 6 mo
−11.9 ± 17.3, −7.7 ± 
19.4), and −8.7 ± 20.8, 
for the patients pre-
treated with 4 mg or 
less, 4–6 mg, and 6 
mg oral risperidone
Improvements were 
reported in all domains 
for the 6 mg pre-trial 
dosage group, signiﬁ  cant 
in Role Physical and Role 
Emotional
53% in the 4 mg, 56% 
in the 4–6 mg, and 62% 
in the 6 mg pre-trial 
oral risperidone dosage 
group, resp; 55% overall
Schmauss 
et al 2007
Young adults 119 patients (age 
18–30 yr)
Consistently improved One third of the patients 
considered themselves 
to be either ‘not ill’ 
or ‘borderline ill’ at 
endpoint compared with 
6 per cent at baseline
Not reported Saleem et al 
2004
Elderly persons 52 patients (age 
65+ yr)
−15.8 ± 19.9 Improvements reported 
in all domains
69% Kissling et al 
2007
Negative symp-
toms
842 patients with 
a PANSS negative 
subscale score 
of 21 or higher, 
which was higher 
than their positive 
subscale score
−15.4 ± 20.4 for total 
PANSS, −2.2 ± 5.9 for 
pos. subscale, −6.1 ± 
6.3 for neg. subscale
Improvements reported 
in all domains
58% Curtis et al 
2008
Schizoaffective 
disorder
119 patients 
(52% male, age 
22–74 yr)
−8.5 70% reported “good” or 
“very good” satisfaction
Not reported Mohl et al 
2004Neuropsychiatric Disease and Treatment 2008:4(5) 924
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experienced sustained remission during follow-up. Change 
in PANSS total score was −14.7 ± 23.0 points (−3.6 ± 7.4 on 
the positive and −5.1 ± 6.8 on the negative subscale); again, 
change from baseline to endpoint was highly signiﬁ  cant 
(p  0.001) for each score.
Early-stage schizophrenia
Patients who experience their ﬁ  rst episode of schizophre-
nia deserve particular attention for several reasons. Their 
initial treatment represents a key intervention point that 
might determine the further course of their disease, and they 
might be more sensitive to side effects from antipsychotic 
drugs (Weiden et al 2007). From the scientiﬁ  c perspective, 
these populations offer the valuable opportunity to study 
the effectiveness and side effects of particular antipsychotic 
medications unconfounded by prior medication. It has been 
shown earlier that time to relapse in such patients is signiﬁ  -
cantly longer (466 vs 205 days) if their ﬁ  rst treatment is with 
oral risperidone rather than with haloperidol, and the overall 
incidence of relapse during the 206-day median treatment 
period was also signiﬁ  cantly lower, 42% as opposed to 55% 
(Schooler et al 2005).
So far only 1 preliminary study has been published 
(Emsley et al 2008) that examined the efﬁ  cacy and safety of 
directly initiated risperidone LAI in 50 previously untreated 
patients with ﬁ  rst-episode psychosis. Almost two thirds of the 
patients achieved remission, and of the 39 (78%) who showed 
a clinical response of 50%, only 4 relapsed. Mean maximum 
increase in ESRS total score was minimal, at 1.4 points (95% 
CI, 0.61–2.10) There was a unusually marked increase in 
body mass index (4.8 ± 3.8 kg/m2), although more than half 
of the patients had remained on the lowest recommended 
dose (25 mg every 2 weeks), but overall treatment was well 
tolerated. Two other open-label studies investigated patients 
who were in the early stages of schizophreniform disorders 
but not necessarily treatment-naive: a subgroup analysis of 
66 young adults (Lasser et al 2007) from the much larger 
12-month trial (see the section of earlier efﬁ  cacy and safety 
data, above), and a 6-month trial in 382 patients at the Uni-
versity of Barcelona who typically had schizophrenia with 
a median duration of 1 year since diagnosis and required 
a change from their previous medication, mainly because 
of non-compliance (42%) and insufﬁ  cient efﬁ  cacy (31%) 
(Parellada et al 2005). The subgroup analysis of young 
patients from the StoRMI trial (Saleem et al 2004) should 
also be considered in this context.
In the subgroup analysis by Lasser et al (2007), improve-
ment of the PANSS score over time in the young adults 
(men aged 18–25, women 18–30) was identical to what 
was seen in older adults. Mean scores on the patients’ sub-
jective ESRS severity ratings for movement disorders and 
the physicians’ ratings of parkinsonism were signiﬁ  cantly 
improved, from 3.1 ± 3.2 at baseline to 1.6 ± 2.4 at endpoint 
(p  0.0001) and from 2.2 ± 2.4 to 1.1 ± 1.8 (p  0.0001), 
respectively. Physician ratings of dyskinesia, akathisia, and 
dystonia were low throughout the study (mean score 1 
for each). In the Spanish study the total PANSS and all its 
subscale scores also improved signiﬁ  cantly, with 40% of 
patients showing a 20% improvement, and good tolerability 
of risperidone LAI with no unexpected adverse events.
Clinical trials in non-
schizophreniform disorders
Oral risperidone carries a labeling that extends beyond 
the classical use of antipsychotics in schizophrenia and 
schizoaffective disorder. With some variability among the 
major pharmaceutical markets, it is also approved to treat 
manic and mixed episodes in bipolar I disorder, psychosis 
or inappropriate behavior in dementia, and irritability in 
children with autistic disorder. The additional therapeutic 
areas where clinical investigations of risperidone LAI have 
been reported include bipolar disorder and borderline per-
sonality disorder.
Borderline personality disorder is notoriously difﬁ  cult 
to treat, and the typical deﬁ  ciencies in impulse control 
which characterizes these patients frequently results in a 
low degree of compliance with medication regimes which 
include antipsychotics such as risperidone. In a small study 
(12 patients), a 6-month treatment course with risperidone 
LAI was associated with signiﬁ  cant improvement on the CGI 
score (t: 5.7–4.0; p  0.01) and in the Global Assessment of 
Functioning (t: −4.5; gl: 10; p  0.01). Clinical improvement 
was robust after the ﬁ  rst month of treatment and tolerability 
was excellent, with treatment-related symptoms limited to 
mild psychomotor slowing and no emergent extrapyramidal 
symptoms observed (az-Marsa et al 2008).
Although acute episodes in bipolar disorder require 
immediate intervention, long-term maintenance therapy is of 
particular importance in this chronic recurrent illness. As in 
schizophrenia, non-adherence to pharmacotherapy (mainly 
the classical regimens of lithium or valproate) is widespread, 
and a major contributor to relapse. Studies suggest that a 
third of bipolar patients fail to take more than 70% of their 
prescribed medication (Scott and Pope 2002). As with other 
antipsychotics, oral risperidone (as a monotherapy or added 
to the basic regimen) has been shown not only to assist the Neuropsychiatric Disease and Treatment 2008:4(5) 925
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treatment of acute manic or depressive episodes but also to 
provide beneﬁ  t in continued pharmacotherapy; replacing or 
supplementing it with the long-acting intramuscular version 
might confer beneﬁ  ts similar to those seen in schizophreni-
form disorders.
In a Canadian 6-month prospective open-label pilot 
trial, in which 49 patients with bipolar disorder who were 
treated with a mood stabilizer and an oral second-generation 
antipsychotic at baseline were randomized to either continue 
their respective antipsychotic regimen or to be switches to 
risperidone LAI, the changeover to injectible risperidone did 
not cause signiﬁ  cant changes in efﬁ  cacy or safety parameters, 
indicating its therapeutic equivalence with oral antipsychotic 
add-on therapies (Yatham et al 2007). A Korean trial with an 
essentially equivalent design which enrolled only 12 patients 
but followed them for 12 months produced similar results 
(Han et al 2007). The Young Mania Rating Scale (YMRS), 
the CGI-S, and the ESRS had been used as outcome mea-
sures in both trials. Preliminary conﬁ  rmatory information to 
this effect is also available for bipolar I and II patients with 
predominantly depressive symptoms who were treated with 
risperidone LAI for 2 years (Malempati et al 2008).
Paliperidone – a new treatment 
opportunity
An interesting potential alternative to risperidone LAI is 
its active metabolite, 9-hydroxy-risperidone (paliperidone), 
which has become available as a drug in its own right for 
the acute and maintenance treatment in 2007. The receptor 
interaction proﬁ  le of paliperidone is essentially the same as 
for its parent drug, ie, its action is believed to be mediated 
mainly through antagonism at dopamine D2 receptors and 
serotonin 5-HT2A receptors while it has little activity at mus-
carinic receptors and hence, little potential for anticholinergic 
side effects while the preponderance for causing hyperpro-
lactinemia can be expected to be the same (Knegtering et al 
2005). The marketed form of paliperidone uses an extended-
release once-daily oral formulation based on an inert osmotic 
tablet. Its clinical efﬁ  cacy has been extensively reviewed 
(Fowler et al 2008; Nussbaum and Stroup 2008).
At therapeutic doses, most of the drug is excreted 
unchanged through the kidneys (Veirmeir et al 2008) and its 
minimal hepatic metabolism might offer a safety advantage 
over its parent drug in patients with liver impairment and 
those who use other prescription drugs which compete with 
risperidone for liver cytochrome 2D6 or induce or inhibit 
it, or those who carry CYP2D6 polymorphisms (Leon et al 
2007). Also, the sustained-release formulation ﬂ  attens the 
pharmacokinetic characteristics of paliperidone. No direct 
comparisons of paliperidone with oral or LAI risperidone 
have been published yet, but in schizophrenic patients 
who had been switched to paliperidone because they had 
remained symptomatic, paliperidone was signiﬁ  cantly more 
effective than placebo (Canuso et al 2008). Most notably, a 
LAI formulation of paliperidone palmitate, based on nano-
crystal technology, is in Phase III clinical development; if 
and when paliperidone LAI is broadly launched, it will be 
particularly rewarding to compare its safety record with that 
of risperidone LAI.
Summary and discussion
The new long-acting formulation of risperidone totally trans-
forms the treatment schedule, from a tablet which the patient 
is asked to swallow once or twice daily to an intramuscular 
injection administered by a healthcare professional every 
2 weeks. From the physician’s perspective the immediate 
points to be made in favor of such an injectable formulation 
concern increased efﬁ  cacy because plasma levels remain 
in the therapeutic window for weeks instead of days, and 
increased drug safety because the potential for overdosing 
(either inadvertent or deliberate, including suicide attempts) 
is virtually eliminated. In both cases the improvement is 
due to the fact that the LAI form removes responsibility for 
adherence to the therapeutic schedule from patients who 
frequently lack insight not only into the nature and severity 
of their condition but also into the consequences of non-
compliance with their medication regimen.
With the top-level data publicly available today it is very 
difﬁ  cult to differentiate any potential direct pharmacokinetic 
beneﬁ  t which risperidone LAI might have over the tablet 
form, beyond what results from the LAI form ensuring drug 
levels in plasma (and by implication, also in the brain) that 
consistently remain in the therapeutic range. However, it 
is fair to assume, in keeping with the long experience with 
ﬁ  rst-generation depot formulations of antipsychotic drugs, 
that ensured compliance is probably responsible for most of 
the increased therapeutic efﬁ  cacy and reduced extrapyramidal 
symptoms of risperidone LAI relative to its oral formulations. 
The risk of hyperprolactinemia, which risperidone shares with 
older neuroleptics, and which can precipitate side effects such 
as sexual dysfunction, infertility, and osteoporosis, cannot be 
expected to be alleviated by a LAI formulation, because the 
active metabolite, 9-OH-risperidone, appears to be responsible 
rather than risperidone itself (Knegtering et al 2005).
While this might well be debated further, it can be deﬁ  -
nitely stated that therapeutic efﬁ  cacy of risperidone LAI in Neuropsychiatric Disease and Treatment 2008:4(5) 926
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schizophreniform disorders is signiﬁ  cant even for patients 
previously treated with oral risperidone (see Schmauss et al 
2007), and that this beneﬁ  t is maintained during continued 
treatment for periods that may exceed 2 years. The time 
course of treatment-emergent events during extended studies 
consistently suggests that patients tend to adapt to risperidone 
LAI treatment early, with a level of extrapyramidal symptoms 
that is equivalent to, or better than, oral risperidone.
The rare but potentially life-threatening cardiac events 
caused by atypical antipsychotics, which are threshold-types 
of events triggered by excessive plasma levels of the drug, 
should be an even less signiﬁ  cant risk with the injectable form 
than it is with risperidone tablets. Indeed, in some studies 
QTc interval prolongation seen with risperidone LAI was 
even lower than with placebo. In this context it should also be 
noted that in most cases the amount of risperidone introduced 
into the patient’s body while using the LAI formulation is 
only about half as high as with the tablet form; typical oral 
doses of 4–6 mg/day are bioequivalent to 25–37.5 mg of 
the LAI form every 2 weeks. Although risperidone is not 
known for causing pronounced gastrointestinal or hepatic 
side effects, reducing the burden on the intestinal drug trans-
porters and on the liver could be beneﬁ  cial in multimedicated 
patients, especially in the elderly.
These obvious beneﬁ  ts should far outweigh the few 
speciﬁ  c risks that any microparticle-based injectable drug 
formulation can be expected to have. Although the mic-
roparticles are designed to decompose in muscle tissue in 
the vicinity of the injection site, it is conceivable that some 
might leak into the circulation intact, either if a minor vein 
is damaged during injection or as a consequence of later tis-
sue trauma near the injection site. Theoretically this could 
cause transient occlusion of capillary microvessels, which 
(probably coupled with the unintended local release of the 
active priciple) could be critical in some tissues, especially 
in capillary retinal vessels. However, no such cases have 
been conclusively demonstrated for risperidone LAI or an 
injectable form of leuprolide acetate which is based on very 
similar microspheres, and has been in use longer.
In summary, risperidone LAI – the ﬁ  rst long-acting inject-
able formulation of a second-generation antipsychotic drug 
to reach the world market – exhibits an efﬁ  cacy and safety 
proﬁ  le which in the clinical practice of schizophrenia and 
schizoaffective disorder treatment is superior to that of the 
tablet formulation. As an add-on therapy in bipolar disorder, 
it appears to be equivalent to the oral formulation in terms of 
both efﬁ  cacy and safety, but published data are still relatively 
limited in this application. As for the several other psychiatric 
disorders where oral risperidone has already been clinically 
investigated, the community can justiﬁ  ably expect more 
clinical studies to be undertaken with risperidone LAI.
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